Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Stock Rating Raised to “Strong-Buy” at Zacks Research

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued on Thursday, Zacks reports.

Separately, Jefferies Financial Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. Three investment analysts have rated the stock with a Strong Buy rating. According to data from MarketBeat, Shionogi & Co., Ltd. Unsponsored ADR presently has a consensus rating of “Strong Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Trading Up 1.0%

Shares of SGIOY traded up $0.09 during midday trading on Thursday, reaching $9.22. The company had a trading volume of 163,940 shares, compared to its average volume of 95,038. Shionogi & Co., Ltd. Unsponsored ADR has a 1-year low of $7.83 and a 1-year high of $12.00. The company has a quick ratio of 1.00, a current ratio of 1.14 and a debt-to-equity ratio of 0.01. The firm has a 50 day simple moving average of $9.07 and a 200-day simple moving average of $9.27. The stock has a market cap of $15.69 billion, a PE ratio of 9.22, a price-to-earnings-growth ratio of 3.27 and a beta of 0.08.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last announced its quarterly earnings results on Monday, August 3rd. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.18. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.13%. The firm had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $970.69 million. Research analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 EPS for the current fiscal year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Osaka. Founded in 1878, the company discovers, develops, manufactures and markets prescription medicines, with a focus on infectious diseases, central nervous system disorders and other areas of unmet medical need.

Shionogi’s portfolio includes Xofluza (baloxavir marboxil), an antiviral treatment for influenza, and F. (fostemsavir), an HIV treatment marketed in certain regions. The company also develops medicines for conditions including pain, psychiatric disorders and other diseases, while pursuing research in areas such as antimicrobial resistance and novel anti-infective therapies.

Shionogi primarily serves the Japanese market and has expanded its international presence through subsidiaries, licensing arrangements and commercial partnerships in North America, Europe and other regions.